Literature DB >> 15262981

Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death.

Kathrin Müntener1, Roman Zwicky, Gabor Csucs, Jack Rohrer, Antonio Baici.   

Abstract

The alternatively spliced messenger RNA of the human cysteine peptidase cathepsin B missing exons 2 and 3 encodes a truncated form of the enzyme lacking the signal peptide and part of the inhibitory propeptide. This deletion results in a new N-terminal leader sequence characteristic of proteins predestined for transport into mitochondria. We determined enzyme targeting to intracellular organelles by transfecting HeLa cells with constructs containing segments of variable length of the N terminus of truncated cathepsin B fused to green fluorescent protein. Co-localization of the constructs with mitochondria and the endoplasmic reticulum was probed with specific markers. None of the chimeric products were found in the endoplasmic reticulum, showing that truncated cathepsin B is misrouted from its regular biosynthetic pathway and forced to enter the mitochondria instead of lysosomes as its final destination. The first 20 amino acids of the new N terminus were necessary and sufficient for mitochondrial targeting, but only cells expressing the complete truncated cathepsin B sequence died by nuclear fragmentation. This new and unexpected behavior draws attention to an additional extralysosomal role for a cysteine peptidase with several recognized important pathophysiological functions. Mitochondrial targeting of cathepsin B may have significant consequences on cell life in pathological or physiological situations characterized by excessive transcription of the cathepsin B message lacking exons 2 and 3, as observed for instance in osteoarthritic cartilage. Copyright 2004 American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262981     DOI: 10.1074/jbc.M405333200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Nuclear cysteine cathepsin variants in thyroid carcinoma cells.

Authors:  Sofia Tedelind; Kseniia Poliakova; Amanda Valeta; Ruth Hunegnaw; Eyoel Lemma Yemanaberhan; Nils-Erik Heldin; Junichi Kurebayashi; Ekkehard Weber; Nataša Kopitar-Jerala; Boris Turk; Matthew Bogyo; Klaudia Brix
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

Review 3.  Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Authors:  Klaudia Brix; Joseph McInnes; Alaa Al-Hashimi; Maren Rehders; Tripti Tamhane; Mads H Haugen
Journal:  Protoplasma       Date:  2014-11-16       Impact factor: 3.356

Review 4.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

5.  Sphingosine kinase-1 is cleaved by cathepsin B in vitro: identification of the initial cleavage sites for the protease.

Authors:  Tarek A Taha; Mazen El-Alwani; Yusuf A Hannun; Lina M Obeid
Journal:  FEBS Lett       Date:  2006-10-12       Impact factor: 4.124

6.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

Review 7.  Cathepsin B: multiple roles in cancer.

Authors:  Neha Aggarwal; Bonnie F Sloane
Journal:  Proteomics Clin Appl       Date:  2014-03-26       Impact factor: 3.494

8.  'Patchiness' and basic cancer research: unravelling the proteases.

Authors:  Surinder M Soond; Maria V Kozhevnikova; Andrey A Zamyatnin
Journal:  Cell Cycle       Date:  2019-06-24       Impact factor: 4.534

9.  Mitochondrial micro-calpain is not involved in the processing of apoptosis-inducing factor.

Authors:  Aashish Joshi; Vimala Bondada; James W Geddes
Journal:  Exp Neurol       Date:  2009-04-23       Impact factor: 5.330

10.  A double-headed cathepsin B inhibitor devoid of warhead.

Authors:  Patricia Schenker; Pietro Alfarano; Peter Kolb; Amedeo Caflisch; Antonio Baici
Journal:  Protein Sci       Date:  2008-09-16       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.